Better Medicines for Children, A DIA/EFGCP Conference

Plan ahead and join us to reflect on the importance of two major headways that are currently affecting Paediatric research: Innovative approaches to Drug Development and impact of the current environment on the Regulatory and Research Infrastructure

Back to Agenda

Session 2: Advanced Therapy Medicinal Products (ATMPs) – Do They Hold What They Promise?

Session Chair(s)

Katie Rizvi

Founder, Little People Association & Temerarii Club

The Romanian Community of Cancer Survivor Adolescents and Young Adults, Romania

Session 2: Advanced Therapy Medicinal Products (ATMPs) – Do They Hold What They Promise?

Speaker(s)

Advances in ATMP Development - Regulator Perspective

Anja Schiel, PhD

Norwegian Medicines Agency (NoMA), Norway

Special Advisor, Lead Methodologist; Leader international HTA (iHTA) NoMA

Paediatric ATMP Development– Industry Initial Learnings

Mette Due Theilade Thomsen, PhD

PIP Adviser, Denmark

CEO

Paediatric ATMP Development– Patients’ Experience

Elizabeth Vroom

Duchenne Parent Project, Netherlands

President

Have an account?

Better Medicines for Children, A DIA/EFGCP Conference

Session 2: Advanced Therapy Medicinal Products (ATMPs) – Do They Hold What They Promise?

Session Chair(s)

Katie Rizvi

Speaker(s)

Advances in ATMP Development - Regulator Perspective

Paediatric ATMP Development– Industry Initial Learnings

Paediatric ATMP Development– Patients’ Experience

Be informed and stay engaged.